Proven: a single-letter edit to a fetal hemoglobin switch can keep severe pain crises away for a year in a single-arm study, as judged by independent reviewers. Not yet shown: how long it lasts beyond that, how it compares head to head with approved options, and what it will cost to deliver at scale. Beam itself flags that treatment effects may not prove durable over longer follow-up.
Risto-cel would arrive third in a market that has been slow. Casgevy and Lyfgenia both sold slowly at first. Genetix, the company formerly known as bluebird bio, sold itself after struggling to market Lyfgenia and its other gene therapies. Only five people received Casgevy in the second half of 2024. The number receiving treatment rose to 64 in 2025, bringing $116 million in revenue, and Vertex booked $219 million in Casgevy sales in the first nine months of 2026.
Beam’s management told analysts in September that uptake has been held back by supply constraints rather than weak demand or reimbursement. RBC analysts add that risto-cel could be attractive because it has a shorter manufacturing process and needs fewer cycles of treatment to mobilise the cells. On the day of the news, Beam’s shares fell by as much as 10%.
Timeline: BEACON data cutoff 20 Oct → topline 10 Nov → ASH oral 12–15 Dec → BLA as early as year-end 2026 → detailed results in 2027.